Copyright
©The Author(s) 2016.
World J Gastroenterol. Jun 21, 2016; 22(23): 5384-5392
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5384
Published online Jun 21, 2016. doi: 10.3748/wjg.v22.i23.5384
Table 3 Type of recurrence
| Type of recurrence | Sorafenib | Control | P value1 |
| Hepatic | 8 | 28 | 0.079 |
| Extrahepatic | 5 | 12 | 0.707 |
| Hepatic + extrahepatic | 2 | 11 | 0.142 |
| Overall hepatic recurrence | 10 | 39 | 0.008 |
| Overall extrahepatic | 7 | 23 | 0.167 |
| Total recurrence | 15 (44.1%) | 51 (75.0%) | 0.002 |
- Citation: Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016; 22(23): 5384-5392
- URL: https://www.wjgnet.com/1007-9327/full/v22/i23/5384.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i23.5384